Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (Nasdaq: EQ) appointed Dr. Y. Katherine Xu to its board of directors, effective February 4, 2021. A partner at Decheng Capital, Dr. Xu brings extensive experience in biotechnology and finance. Her expertise is expected to enhance Equillium’s strategic direction as the company advances into later-stage development of itolizumab, aimed at treating severe autoimmune disorders. Dr. Xu noted the significance of targeting the CD6-ALCAM pathway, particularly after promising interim results for treating acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) has successfully closed a registered direct offering, raising approximately $30 million in gross proceeds. The offering included 4,285,710 units, with each unit comprising one share of common stock and a warrant for an additional 0.3 shares, priced at $7.00 per unit. The exercise price of the warrants is set at $14.00 per share. Proceeds from this offering will primarily fund the development of the itolizumab pipeline, potential acquisitions, and general corporate purposes.
Equillium, Inc. (Nasdaq: EQ) announced a securities purchase agreement to sell 4,285,710 units at $7.00 each, raising approximately $30 million. Each unit consists of one share of common stock and a warrant for 0.3 additional shares at an exercise price of $14.00. The funds will be used for developing the itolizumab pipeline, acquiring new products, and general corporate needs. The offering closes on February 5, 2021. This offering is registered under a shelf registration statement with the SEC.
Equillium, Inc. (Nasdaq: EQ) announced that interim data from its Phase 1b/2 EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) will be presented as a late-breaking oral session at the 2021 TCT Meetings, scheduled for February 12, 2021. The study, led by John Koreth, aims to demonstrate the safety and efficacy of itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM pathway, important in T cell activity related to autoimmune disorders. Equillium is focused on treating severe autoimmune and inflammatory conditions with high unmet medical needs.
Equillium, a clinical-stage biotechnology company, announced that its CEO Bruce Steel will present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am EST. This presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders. A webcast of the presentation will be accessible on the company’s website under the “Investors” section for 30 days following the event.
Equillium is dedicated to addressing high unmet medical needs in severe immuno-inflammatory diseases.
Equillium Strengthens Leadership with New Executive Appointments
Equillium, Inc. has announced key executive appointments, including Dolca Thomas, M.D., as executive vice president of research and development and chief medical officer. Dr. Thomas has extensive experience from Principia Biopharma and Roche. The company also appointed Michael Son, Ph.D., Nelson Lugo, and Michael Moore to key roles. These strategic hires aim to advance the development of itolizumab for severe autoimmune diseases, particularly acute graft versus host disease, with several critical readouts expected in the coming year.
Equillium, Inc. presented significant findings regarding itolizumab at the 2020 American Society of Hematology Annual Meeting. The study highlighted the drug's ability to suppress the activity of CD4 and CD8 T cells in patients with acute graft-versus-host disease (aGVHD). With no approved first-line therapies for aGVHD, itolizumab's mechanism of targeting the CD6-ALCAM pathway shows promise. Early data from the EQUATE Phase 1b study also supports its potential role in combination with steroids for treating aGVHD.
Equillium, Inc. (Nasdaq: EQ) has announced a virtual Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to 12:00 p.m. ET, focusing on its leading drug candidate, itolizumab, a monoclonal antibody for treating severe autoimmune disorders, including aGVHD, lupus, and uncontrolled asthma. Key presentations will feature Dr. John Koreth from Dana-Farber Cancer Institute and the company's executives. Following presentations, there will be a Q&A session. A webcast will be available for 30 days on the company's Investor Relations website.
Equillium has announced it will not proceed with the EQUINOX Phase 3 clinical trial for itolizumab in COVID-19 patients, citing advancements in vaccines and treatments. CEO Bruce Steel emphasized the decision was strategic amidst a changing treatment landscape. Instead, the company will focus on expanding the itolizumab program for acute graft-versus-host disease, lupus, and asthma studies. The next pipeline updates are expected on December 4, coinciding with the Analyst Day.
Equillium, Inc. (Nasdaq: EQ) announced its Q3 2020 financial results, highlighting a net loss of $6.6 million, or $(0.31) per share, compared to a loss of $6.0 million, or $(0.35) per share in Q3 2019. The company reported a 100% response rate in cohort 3 and an 80% overall response rate in the EQUATE trial for severe aGVHD. It raised $53.0 million in net proceeds, boosting cash reserves to $90.5 million. Upcoming trials include the Phase 3 EQUINOX for COVID-19 patients, set to start this quarter, with initial data expected mid-2021.